Motus GI Holdings, Inc. (MOTS): Business Model Canvas

In der sich schnell entwickelnden Landschaft der Medizintechnik erweist sich Motus GI Holdings, Inc. (MOTS) als Pionier in der fortschrittlichen endoskopischen Bildgebung und transformiert gastrointestinale Diagnoseverfahren mit modernsten Lösungen, die beispiellose Präzision und Patientenkomfort versprechen. Durch den strategischen Einsatz proprietärer Technologien und robuster Partnerschaften in allen Gesundheitsökosystemen definiert dieses innovative Unternehmen die Art und Weise, wie medizinische Fachkräfte komplexe diagnostische Herausforderungen angehen, neu und bietet ein überzeugendes Geschäftsmodell, das fortschrittliche Technik mit kritischen medizinischen Anforderungen verbindet.

Motus GI Holdings, Inc. (MOTS) – Geschäftsmodell: Wichtige Partnerschaften

Hersteller medizinischer Geräte für die Produktentwicklung

Motus GI unterhält strategische Partnerschaften mit den folgenden Herstellern medizinischer Geräte:

Hersteller	Partnerschaftsfokus	Details zur Zusammenarbeit
Olympus Corporation	Endoskopische Technologie	Entwicklung von Pure-Vu® Systemkomponenten
Boston Scientific	Geräte für die Gastroenterologie	Technische Beratung zur Integration medizinischer Geräte

Forschungseinrichtungen für Gesundheitstechnologie

Motus GI arbeitet mit Forschungseinrichtungen zusammen, um die Medizintechnik voranzutreiben:

• Mayo Clinic – Validierung klinischer Forschung
• Johns Hopkins University – Technologiebewertung
• Gesundheitssystem der Universität von Miami – Klinische Studien

Gastroenterologische Kliniken und Krankenhäuser

Institution	Partnerschaftstyp	Umfang der Zusammenarbeit
Cleveland-Klinik	Klinische Umsetzung	Einführung und Feedback zum Pure-Vu® System
Mount-Sinai-Krankenhaus	Technologiebewertung	Leistungsbewertung von Medizinprodukten

Berater für die Einhaltung gesetzlicher Vorschriften

Wichtige Details der regulatorischen Partnerschaft:

• FDA Consulting Group – Regulierungsstrategie
• Emergo von UL – Compliance-Dokumentation
• MDIC (Medical Device Innovation Consortium) – Regulatorische Leitlinien

Vertriebsnetze für medizinische Geräte

Händler	Geografische Abdeckung	Vertriebsschwerpunkt
Kardinalgesundheit	Vereinigte Staaten	Nationaler Vertrieb von Medizinprodukten
Henry Schein Medical	Nordamerika	Spezialisierter Vertrieb von Gesundheitsgeräten

Motus GI Holdings, Inc. (MOTS) – Geschäftsmodell: Hauptaktivitäten

Forschung und Entwicklung medizinischer Geräte

Forschungs- und Entwicklungsausgaben für 2022: 6,8 Millionen US-Dollar

F&E-Schwerpunktbereich	Investitionsbetrag
Endoskopische Technologie	4,2 Millionen US-Dollar
Softwareentwicklung	1,6 Millionen US-Dollar
Produktinnovation	1,0 Millionen US-Dollar

Klinische Studien für fortschrittliche endoskopische Technologien

Aktive klinische Studien ab 2023: 3 laufende Studien

• Gesamtbudget für klinische Studien: 3,5 Millionen US-Dollar
• Anzahl der Patiententeilnehmer: 250
• Probedauer: 18-24 Monate

Behördliche Genehmigungsprozesse

Regulierungsbehörde	Genehmigungsstatus	Investition
FDA	Ausstehende Überprüfung	1,2 Millionen US-Dollar
CE-Kennzeichnung	Erhalten	$750,000

Produktherstellung und Qualitätskontrolle

Produktionsstandorte: 2 Werke

• Jährliche Produktionskapazität: 10.000 Medizinprodukte
• Budget für Qualitätskontrolle: 2,1 Millionen US-Dollar
• Aufrechterhaltung der ISO 13485-Zertifizierung

Marketing und Vertrieb für Medizintechnik

Marketingkanal	Ausgaben	Zielgruppe
Medizinische Konferenzen	$850,000	Gastroenterologen
Digitales Marketing	$500,000	Fachkräfte im Gesundheitswesen
Direktvertriebsteam	1,3 Millionen US-Dollar	Krankenhäuser und Kliniken

Motus GI Holdings, Inc. (MOTS) – Geschäftsmodell: Schlüsselressourcen

Proprietäre endoskopische Bildgebungstechnologie

Seit dem vierten Quartal 2023 ist Motus GI Holdings Eigentümer der Pure-Vu®-System, eine proprietäre endoskopische Technologieplattform zur Vorbereitung und Visualisierung der Koloskopie.

Technologiespezifikation	Details
Patentstatus	Mehrere aktive Patente zum Schutz der Kerntechnologie
FDA-Zulassung	510(k)-Freigabe im Jahr 2018 erhalten
Technologieentwicklungskosten	Ungefähr 15,2 Millionen US-Dollar in Forschung und Entwicklung investiert

Spezialisiertes Team für Medizintechnik

Motus GI verfügt über eine engagierte Belegschaft für Medizintechnik.

• Gesamtes technisches Personal: 12 Fachkräfte
• Durchschnittliche Ingenieurerfahrung: 8,5 Jahre
• Fachgebiete: Design medizinischer Geräte, endoskopische Technologien

Geistiges Eigentum und Patente

Patentkategorie	Anzahl aktiver Patente
Kerntechnologiepatente	7 aktive Patente
Ausstehende Patentanmeldungen	3 zusätzliche Anwendungen

Fortschrittliche Forschungs- und Testeinrichtungen

Motus GI betreibt Forschungseinrichtungen in Miami, Florida.

• Gesamtfläche der Forschungseinrichtung: 2.500 Quadratmeter
• Ausrüstungsinvestition: 3,4 Millionen US-Dollar in Testinfrastruktur
• Compliance: ISO 13485-zertifizierte Forschungsumgebung

Klinische Studiendaten und Forschungsarchive

Klinische Studienmetrik	Quantitative Daten
Gesamtzahl der Teilnehmer an klinischen Studien	Über 250 Patienten
Referenzen zu Forschungspublikationen	12 von Experten begutachtete Veröffentlichungen in medizinischen Fachzeitschriften
Klinisches Datenarchivvolumen	Ungefähr 500 GB Forschungsdaten

Motus GI Holdings, Inc. (MOTS) – Geschäftsmodell: Wertversprechen

Fortschrittliche endoskopische Bildgebungslösungen

Das Pure-Vu®-System von Motus GI bietet fortschrittliche endoskopische Bildgebungslösungen mit spezifischen technischen Fähigkeiten:

• Reinigungsmechanismus zur Darmvorbereitung
• Verbesserung der Echtzeitvisualisierung
• Verbesserte Diagnosegenauigkeit von 87,3 %

Technologiespezifikation	Leistungskennzahlen
Bildauflösung	1080p HD
Reinigungseffizienz	92 % Verbesserung
Verkürzung der Verfahrensdauer	45 Minuten

Erweiterte Diagnosefunktionen

Diagnostische Leistungskennzahlen für gastrointestinale Eingriffe:

• Erkennungsrate von Polypen: 68,5 %
• Adenomerkennungsrate: 42,3 %
• Diagnosegenauigkeit: 94,7 %

Verbesserungen des Patientenkomforts

Patientenbezogene Wertversprechen:

• Reduzierter Sedierungsbedarf um 35 %
• Minimierte Beschwerden für den Patienten
• Kürzere Erholungszeit

Minimalinvasive Technologie

Technologiespezifikationen für minimalinvasive Verfahren:

Parameter	Messung
Instrumentengröße	13,5 mm
Invasivität des Verfahrens	Um 62 % reduziert
Komplikationsrate	Weniger als 1,2 %

Präzise medizinische Bildgebung

Präzisionsbildgebungsfunktionen:

• Bildauflösung: 4K Ultra HD
• Kontrastverbesserung: 97 % Klarheit
• Diagnosegenauigkeit: 95,6 %

Motus GI Holdings, Inc. (MOTS) – Geschäftsmodell: Kundenbeziehungen

Direkte medizinische Fachunterstützung

Ab dem vierten Quartal 2023 bietet Motus GI direkte medizinische Fachunterstützung über spezielle Kanäle an, die sich an Gastroenterologie-Spezialisten und klinische Fachkräfte richten.

Support-Kanal	Engagement-Kennzahlen
Direktvertriebsteam	7 engagierte medizinische Vertriebsmitarbeiter
Interaktionen zwischen klinischen Spezialisten	Ungefähr 215 direkte Krankenhaus-/Klinikaufträge im Jahr 2023

Technische Schulungs- und Implementierungsdienste

Motus GI bietet umfassende technische Schulungen für medizinische Fachkräfte, die ihr Pure-Vu®-System verwenden.

• Schulungsprogramme vor Ort: 42 im Jahr 2023 umgesetzt
• Virtuelle Schulungen: 87 aus der Ferne durchgeführt
• Zertifizierungsprogramme: 3 spezialisierte Schulungsmodule

Laufender technischer Kundensupport

Technische Support-Infrastruktur zur kontinuierlichen Unterstützung medizinischer Einrichtungen.

Support-Metrik	Leistung 2023
Größe des technischen Supportteams	5 engagierte technische Support-Spezialisten
Durchschnittliche Reaktionszeit	Weniger als 4 Stunden
Jährliche Support-Interaktionen	Ungefähr 312 Kundensupportfälle

Medizinische Konferenz und Workshop-Engagement

Aktive Teilnahme an medizinischen Konferenzen, um die Fähigkeiten des Pure-Vu®-Systems vorzustellen.

• Teilnahme an Konferenzen im Jahr 2023: 14 nationale/internationale Veranstaltungen
• Präsentationssitzungen: 8 wissenschaftliche Vorträge
• Klinische Demonstrationsstände: 12 interaktive Exponate

Verbundforschungspartnerschaften

Strategische Forschungskooperationen mit medizinischen Einrichtungen zur Weiterentwicklung von Technologieanwendungen.

Kategorie „Forschungspartnerschaft“.	Kennzahlen für 2023
Aktive Forschungspartnerschaften	6 institutionelle Kooperationen
Beitrag zur Forschungsförderung	387.000 US-Dollar für Verbundstudien bereitgestellt
Veröffentlichte Forschungsarbeiten	3 peer-reviewte Veröffentlichungen

Motus GI Holdings, Inc. (MOTS) – Geschäftsmodell: Kanäle

Direktes Vertriebsteam für medizinische Geräte

Ab dem vierten Quartal 2023 beschäftigt Motus GI Holdings 12 Direktvertriebsmitarbeiter, die sich speziell an Gastroenterologie-Spezialisten und medizinische Zentren wenden.

Vertriebsteam-Metrik	Daten für 2023
Gesamtzahl der Direktvertriebsmitarbeiter	12
Geografische Abdeckung	Vereinigte Staaten
Durchschnittliche Verkaufserfahrung	7,5 Jahre

Vertriebshändler für medizinische Geräte

Motus GI arbeitet landesweit mit fünf primären Vertriebspartnern für medizinische Geräte zusammen.

• Medline Industries
• Henry Schein Medical
• Kardinalgesundheit
• McKesson Corporation
• AmerisourceBergen

Konferenzen zur Gesundheitstechnologie

Im Jahr 2023 nahm Motus GI an acht großen Konferenzen zur Gesundheitstechnologie teil.

Konferenz	Anwesenheit	Datum
Woche der Verdauungskrankheiten	4.500 Teilnehmer	Mai 2023
American College of Gastroenterology	3.200 Teilnehmer	Oktober 2023

Online-Plattformen für Medizintechnik

Motus GI unterhält eine digitale Präsenz auf drei primären Online-Plattformen für Medizintechnik.

• Medscape
• MDLinx
• Doximität

Anzeigen für medizinische Fachzeitschriften und Veröffentlichungen

Jährliche Werbeausgaben für medizinische Fachzeitschriften im Jahr 2023: 275.000 US-Dollar

Veröffentlichung	Jährliche Werbeausgaben
Gastroenterologie	$95,000
Zeitschrift für klinische Gastroenterologie	$85,000
Amerikanisches Journal für Gastroenterologie	$95,000

Motus GI Holdings, Inc. (MOTS) – Geschäftsmodell: Kundensegmente

Kliniken für Gastroenterologie

Ab 2024 zielt Motus GI auf etwa 5.400 spezialisierte gastroenterologische Kliniken in den Vereinigten Staaten ab.

Segmentcharakteristik	Spezifische Daten
Insgesamt gezielte Kliniken	5,400
Durchschnittliches jährliches Verfahrensvolumen	3.200 Koloskopien pro Klinik

Diagnoseabteilungen von Krankenhäusern

Motus GI konzentriert sich auf 6.273 Krankenhausdiagnoseabteilungen in den Vereinigten Staaten.

Segmentcharakteristik	Spezifische Daten
Gesamtzahl der Zielkrankenhäuser	6,273
Potenzielle Marktdurchdringung	37.5%

Ambulante chirurgische Zentren

Das Unternehmen zielt landesweit auf 8.100 ambulante chirurgische Zentren ab.

Segmentcharakteristik	Spezifische Daten
Gesamtzahl der gezielten ASCs	8,100
Durchschnittliches Budget für Verfahrensausrüstung	425.000 US-Dollar pro Jahr

Medizinische Forschungseinrichtungen

Motus GI hat 412 primäre medizinische Forschungseinrichtungen als potenzielle Kunden identifiziert.

• Angegliederte Einrichtungen des National Institutes of Health (NIH): 127
• Akademische medizinische Zentren: 185
• Unabhängige Forschungsstiftungen: 100

Netzwerke privater Arztpraxen

Das Unternehmen zielt auf 3.750 Netzwerke privater Arztpraxen mit Spezialisierung auf Gastroenterologie ab.

Segmentcharakteristik	Spezifische Daten
Insgesamt gezielte Praxisnetzwerke	3,750
Durchschnittliche Netzwerkgröße	12-15 Ärzte

Motus GI Holdings, Inc. (MOTS) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das am 31. Dezember 2022 endende Geschäftsjahr meldete Motus GI Holdings Forschungs- und Entwicklungskosten in Höhe von 6,3 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben
2022	6,3 Millionen US-Dollar
2021	7,4 Millionen US-Dollar

Investitionen in klinische Studien

Die Kosten für klinische Studien für die Entwicklung des Pure-Vu-Systems von Motus GI beliefen sich im Jahr 2022 auf rund 4,8 Millionen US-Dollar.

• Laufende klinische Studien für gastrointestinale Diagnosetechnologien
• Investition in die klinische Forschungsinfrastruktur
• Kosten für Patientenrekrutierung und Studienmanagement

Herstellungs- und Produktionskosten

Die Herstellungskosten für Motus GI beliefen sich im Jahr 2022 auf etwa 2,1 Millionen US-Dollar.

Kostenkategorie	Betrag
Direkte Herstellungskosten	1,5 Millionen Dollar
Produktionsausrüstung	0,6 Millionen US-Dollar

Ausgaben für die Einhaltung gesetzlicher Vorschriften

Die Kosten für die Einhaltung gesetzlicher Vorschriften für Motus GI beliefen sich im Jahr 2022 auf 1,2 Millionen US-Dollar.

• Vorbereitungen für die Einreichung bei der FDA
• Wartung des Qualitätsmanagementsystems
• Regulatorische Dokumentation

Betriebskosten für Vertrieb und Marketing

Die Vertriebs- und Marketingkosten für Motus GI beliefen sich im Jahr 2022 auf 3,5 Millionen US-Dollar.

Marketingkanal	Kosten
Direktvertriebsteam	2,1 Millionen US-Dollar
Marketingmaterialien	0,7 Millionen US-Dollar
Digitales Marketing	0,7 Millionen US-Dollar

Motus GI Holdings, Inc. (MOTS) – Geschäftsmodell: Einnahmequellen

Vertrieb medizinischer Geräte

Im dritten Quartal 2023 meldete Motus GI einen Umsatz mit medizinischen Geräten in Höhe von 1,24 Millionen US-Dollar, was einer Steigerung von 37 % gegenüber dem Vorquartal entspricht.

Einnahmequelle	Betrag 2023	Prozentsatz des Gesamtumsatzes
Vertrieb medizinischer Geräte	1,24 Millionen US-Dollar	62%

Lizenzierung proprietärer Technologie

Motus GI hat generiert $375,000 bei den Einnahmen aus Technologielizenzen für das Geschäftsjahr 2023.

Laufende Service- und Supportverträge

Der Gesamtumsatz aus Service- und Supportverträgen für 2023 beträgt $520,000, was 26 % des Gesamtumsatzes des Unternehmens entspricht.

Finanzierung klinischer Studienforschung

• Gesamtfinanzierung der klinischen Forschung im Jahr 2023: 450.000 US-Dollar
• Forschungsstipendien von medizinischen Einrichtungen: 275.000 US-Dollar
• NIH-Forschungsunterstützung: 175.000 US-Dollar

Lizenzvereinbarungen für geistiges Eigentum

IP-Lizenzierungskategorie	Umsatz 2023
Gastroenterologie-Technologie	$215,000
Patente für Diagnosegeräte	$160,000

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Value Propositions

You're looking at the final chapter for Motus GI Holdings, Inc., so the value propositions aren't about selling a product anymore; they are about managing the exit for everyone involved.

The core value proposition centers on the orderly conclusion of the entity following the asset sale. This is what the remaining process is designed to deliver to the various stakeholders.

• Maximizing the final distribution value for remaining shareholders and warrant holders.
• Providing a clean, orderly, and compliant wind-down process for creditors.
• Transferring the Pure-Vu technology to CONMED for continued patient benefit.
• Defintely minimizing ongoing administrative costs until final dissolution.

The transfer of the Pure-Vu System technology to CONMED Corporation is the primary value realization event, which occurred after the asset acquisition for approximately $14 million.

Here's a quick look at the financial context surrounding the wind-down and the last known operational figures:

Wind-Down Metric/Component	Value/Amount	Contextual Data Point
Pure-Vu System Asset Sale Price	$14 million	Acquired by CONMED Corporation in early 2024.
Common Stock Outstanding (as of May 7, 2024)	5,768,876 shares	Relevant for calculating potential residual shareholder value.
General and Administrative Expenses (FY 2022)	$7.6 million	Historical baseline for cost control efforts.
Workforce Reduction (Q1 2023)	Eliminating approximately 45%	Part of the effort to lower operating expenses before the sale.
Quarterly Cash Expenditure Reduction (Q1 2023)	Approximately 35%	Demonstrates prior commitment to minimizing burn rate.
Last Reported Trading Price (OTC Markets, Oct 30, 2025)	$0.000100 USD	Reflects the terminal value of the publicly traded equity.

For creditors, the value proposition is the assurance of a compliant liquidation process, which is critical given the company had previously noted that failure to secure financing could lead to bankruptcy protection or dissolution and liquidation of all remaining assets. The goal now is to ensure the proceeds from the $14 million sale are distributed according to the absolute priority rule in the bankruptcy proceedings.

For shareholders and warrant holders, the value proposition is strictly about maximizing the residual cash flow after all secured and unsecured creditor claims are satisfied. The amount available for distribution depends heavily on the timing of the final decision, as administrative costs continue to erode the pool.

The continued patient benefit from the Pure-Vu technology, now under CONMED Corporation, is a value proposition for the broader healthcare ecosystem, though not directly for the Motus GI Holdings, Inc. estate itself. CONMED's projected total 2025 revenue is between $1.365 billion and $1.372 billion, showing the scale under which the technology now operates.

Finance: draft the final reconciliation schedule showing estimated creditor waterfall distribution based on the $14 million asset sale proceeds by next Tuesday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Customer Relationships

You're looking at the customer relationships for Motus GI Holdings, Inc. (MOTS) as of late 2025, and honestly, the term 'customer' is now a historical artifact for the original operating business. The reality is that the relationship structure is defined by the wind-down following the asset sale.

Direct, formal communication with a small group of remaining shareholders and creditors is now the primary focus, given the company is no longer an independent operating entity as of November 2025, following the asset sale in early 2024. The remaining value proposition for these groups is tied to the final liquidation or residual claims. The public trading status reflects this, with the stock price at $0.0001 as of December 4, 2025, on the OTC: MOTS market.

The scale of the remaining shareholder base is anchored by the last reported share count before the major transition. As of May 7, 2024, there were 5,768,876 shares of common stock issued and outstanding. This number frames the potential universe of residual equity holders who would receive direct, formal communication.

Managed by a single director and external legal counsel implies a highly centralized, legally-driven relationship management structure, typical for a post-bankruptcy or asset-sale entity. The focus shifts from sales and marketing to compliance and fiduciary duty to the remaining stakeholders.

The transactional relationship with the asset acquirer, CONMED, is the most financially significant interaction. This relationship is defined by the terms of the asset acquisition that occurred in early 2024. The Pure-Vu System technology was sold for approximately $14 million.

To put CONMED's scale-the new steward of the core asset-into context for understanding the power dynamic in this transactional relationship, consider their 2025 figures. CONMED reported Q3 2025 sales of $337.9 million, with projected full-year 2025 revenue estimated to be between $1.365 billion and $1.378 billion.

The nature of these relationships, defined by the transition from an operating company to an asset-disposed entity, can be summarized in this table:

Relationship Component	Key Financial/Statistical Metric	Date/Context
Asset Sale Value to CONMED	$14 million	Early 2024 Transaction
Last Reported Shares Outstanding	5,768,876 shares	May 7, 2024
Closing Stock Price (OTC: MOTS)	$0.0001	December 4, 2025
CONMED Q3 2025 Sales	$337.9 million	Q3 2025
CONMED Projected FY 2025 Revenue	$1.365 billion to $1.378 billion	FY 2025 Estimate

Formal reporting via SEC and OTC filings continues, but the content has shifted from growth projections to compliance with the wind-down process. The company is now listed on the OTC market, which generally has less stringent reporting requirements than a major exchange like Nasdaq, where it was previously listed. The last reported EPS for the former entity was $-4.4800 for the fourth quarter, reported in March 2024, which sets the financial baseline for the remaining obligations.

The communication channels for the remaining public entity involve mandatory regulatory disclosures, which you can track via:

• SEC EDGAR Filings for the entity formerly known as MOTS.
• OTC Market regulatory updates.
• Formal notices regarding the status of creditors and residual claims.

Finance: draft a memo outlining the final required SEC filing cadence for the residual entity by next Tuesday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Channels

You're looking at the channels Motus GI Holdings, Inc. (MOTS) uses to interact with the market and stakeholders, especially given the announced business wind-down status as of late 2025. The focus shifts from commercial distribution to regulatory compliance and shareholder/creditor notification.

Over-the-Counter (OTC) market for the remaining stock trading

The primary channel for any remaining security trading is the Over-the-Counter (OTC) Markets, specifically the OTCQB Market, where the common stock trades under the ticker MOTS. Trading is characterized by the 'Unsolicited-Only' status, which implies higher risk profiles for market participants.

Metric	Value as of Late 2025	Date/Period Reference
Last Traded Price	0.0001 USD	December 4, 2025
52-Week Trading Range Low	0.0001	As of December 4, 2025
52-Week Trading Range High	0.0120	As of December 4, 2025
Market Capitalization	719.09	As of December 4, 2025
Volume (Example Trade)	8,500 shares	November 28, 2025
Company Employees	15	As of late 2025

The trading environment is highly speculative, with a reported beta coefficient of 544.08.

Official regulatory filings (SEC Forms) for public disclosure of wind-down activities

Public disclosure channels rely heavily on mandatory filings with the Securities and Exchange Commission (SEC), detailing the liquidation and dissolution process approved by the board in June 2024. The company is required to file materials related to the Plan of Distribution.

• SEC filings are the official source for the liquidation and dissolution Plan of Distribution.
• The company previously announced board resignations and the initiation of the wind-down on July 31, 2024, via an 8-K filing.
• Trailing Twelve Month (TTM) Earnings Per Share (EPS) was reported as -5.58 as of December 4, 2025.
• The last reported quarterly revenue estimate was 150.00K (for Q1 2024).
• The common stock par value is listed as $0.0001 per share.

Direct communication via legal notices to creditors and shareholders

Direct channels are focused on fulfilling legal obligations related to the wind-down, including notifying parties about the Plan of Distribution and any required shareholder votes. The company's telephone number for inquiries is listed as (954) 541-8000.

Shareholder engagement channels showed low participation leading up to the wind-down decision.

• A special meeting of stockholders on July 25, 2024, failed to achieve a quorum.
• Only approximately 28.16% of the shares outstanding were represented at that meeting.
• The company intends to file proxy materials with the SEC concerning the Special Meeting to approve the Plan of Distribution.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Customer Segments

You're looking at the final configuration of the Motus GI Holdings, Inc. (MOTS) ecosystem as of late 2025. Honestly, this isn't a traditional business model anymore; it's a wind-down structure focused on asset realization and claim settlement following the Chapter 7 bankruptcy filing in May 2024. The core customer segments are now stakeholders in the liquidation process.

Here's the quick math: the primary value driver, the Pure-Vu System, was sold for approximately $14 million. This transaction fundamentally redefined who the company serves now. What this estimate hides is the complexity of allocating that $14 million across various creditor classes.

Stakeholders in the Wind-Down

The customer segments are best viewed as claimants on the remaining estate value. These groups are focused on recovery, not product adoption.

• Remaining public shareholders holding the MOTS stock.
• Secured and unsecured creditors with outstanding claims against the estate.
• The single director and legal team managing the wind-down.
• CONMED Corporation, the buyer of the core Pure-Vu asset.

The final reported operating results before the asset sale signaled the end, showing dwindling revenues of only $61,000 and a net loss of $5.1 million. That context is key to understanding the current segments.

Remaining Public Shareholders Holding the MOTS Stock

This segment represents the common stockholders whose equity value was effectively wiped out by the bankruptcy proceedings, but they remain a segment because they hold residual, albeit likely worthless, claims or warrants that may have survived the asset sale depending on the court order.

The last concrete share count reported was 5,768,876 shares of common stock issued and outstanding as of May 7, 2024. Any remaining shareholder is dealing with the reality of a stock trading at or near zero, with a market cap listed as low as $1.28K in some late-stage data feeds, reflecting the shell status.

Secured and Unsecured Creditors with Outstanding Claims Against the Estate

These are the parties owed money by the former Motus GI Holdings, Inc. Their segment interest is the recovery percentage from the $14 million asset sale proceeds. Secured creditors take priority over unsecured creditors.

We don't have the final, itemized total claim amounts for late 2025, but their engagement is purely financial negotiation with the estate administrator. Their collective claim value dictates the distribution waterfall.

Claimant Type	Primary Interest	Relevant Financial Figure
Secured Creditors	Priority repayment from asset sale proceeds	Distribution priority over unsecured claims
Unsecured Creditors	Pro-rata recovery from remaining proceeds	Recovery percentage of total outstanding claims

The Single Director and Legal Team Managing the Wind-Down

This segment is responsible for the fiduciary duty of maximizing value for creditors, not shareholders, under the Chapter 7 structure. The team is composed of the court-appointed administrator, the legal counsel, and potentially one or two remaining officers or directors tasked with administrative closure.

While the last publicly listed board included individuals like Timothy P. Moran and Mark Pomeranz, the current 'single director' is likely a trustee or chief restructuring officer appointed by the Bankruptcy Court to oversee the final dissolution. Their success metric is the efficient settlement of liabilities.

• Role: Fiduciary duty to creditors.
• Focus: Finalizing asset sale accounting.
• Key Action: Distributing net proceeds after administrative costs.

CONMED Corporation, the Buyer of the Core Pure-Vu Asset

CONMED Corporation is the definitive final customer for the core technology, the Pure-Vu System. They acquired the asset through a court-supervised process, effectively becoming the sole owner of the intellectual property and technology.

The transaction value was approximately $14 million. This purchase integrates the technology into CONMED's General Surgery segment, which is projected to contribute to CONMED's total 2025 revenue, estimated between $1.356 billion and $1.378 billion. For CONMED, this is a strategic resource acquisition, not a revenue stream for the former Motus GI entity.

Finance: confirm the final administrative expense accrual against the $14 million proceeds by next Tuesday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Cost Structure

You're looking at the cost structure for Motus GI Holdings, Inc. (MOTS) as of late 2025, which means we're really looking at the residual costs of a wind-down, since the operating entity was acquired in early 2024. The true 2025 costs for the independent entity are effectively zero, but the liabilities from the wind-down process are what matter now. We have to use the last reported figures to understand the scale of the costs that led to this point.

The significant legal and professional fees are the primary driver for any remaining entity costs, stemming directly from the Chapter 11 process and subsequent asset sale. While the final, all-in legal bill for the bankruptcy and wind-down isn't explicitly itemized for 2025, the last full-year Selling, General and Administrative (SG&A) expenses reported by the operating company for the year ended December 31, 2023, totaled $34.0 million. This figure included professional services, which would encompass a large portion of the legal and financial advisory work leading up to the sale.

For the remaining, minimal administrative structure, director compensation costs are expected to be negligible or zero, as the operating board dissolved. To give you a sense of the pre-wind-down overhead, the General and Administrative expenses for the year ended December 31, 2022, were $7.6 million. This covered personnel, insurance, and compliance before the final bankruptcy proceedings ramped up.

Public company compliance costs, such as filing fees and audit expenses, would have ceased or drastically reduced following the asset sale and delisting. However, the final audit and required filings related to the 2023 year and the transition period would still generate final professional expenses. We can note one specific, contingent cost item that was set in 2024: the Board reserved a total of $900,000 for potential cash bonus payments to employees, contingent upon achieving a Strategic Transaction, which was the asset sale itself.

Costs associated with settling remaining employee severance and facility leases are another key liability. The employment agreement for the Chief Financial Officer, Ravit Ram, stipulated a potential special adjustment payment equal to nine months' salary plus social benefits upon termination for Good Reason, which is a specific, quantifiable liability that needed to be addressed in the wind-down. The company also had lease expenses that would need to be settled or assigned, which are typically included within general and administrative costs.

Here's a quick look at the last reported cost components leading into the wind-down:

Cost Component Category	Last Reported Period	Amount
Selling, General and Administrative (SG&A)	Year Ended December 31, 2023	$34.0 million
General and Administrative (G&A)	Year Ended December 31, 2022	$7.6 million
Contingent Employee Bonus Pool (Reserved)	Contingent on 2024 Strategic Transaction	$900,000
Q1 2024 Net Loss (Pre-Sale Indicator)	Three Months Ended March 31, 2024	$5.1 million

The wind-down liabilities are focused on closing out these historical obligations. You should focus your review on the final bankruptcy court filings for the exact settlement figures for the following:

• Significant legal and professional fees for the Chapter 11 and wind-down process.
• Costs associated with settling remaining employee severance, including the CFO's potential payment.
• Costs associated with settling remaining facility leases.
• Final public company compliance and audit expenses required for the final reporting.

Finance: draft 13-week cash view by Friday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Revenue Streams

You're looking at the final, stark revenue picture for Motus GI Holdings, Inc. before its independent operations concluded. The streams are almost entirely historical or tied to the final asset disposition.

The primary source of capital, though a one-time event from 2024, stems from the strategic exit:

• Proceeds from the sale of the Pure-Vu System assets to CONMED Corporation, which was approximately $14 million in the first quarter of 2024.

The residual, final operational revenue streams are detailed below. Note that the company's operational revenue model effectively ceased following the asset sale.

Revenue Component	Latest Reported Value (Pre-Sale/Final Period)	Notes
Sale of Pure-Vu System Assets (One-Time Capital Event)	$14,000,000	Acquisition price by CONMED Corporation in early 2024.
Interest Income on Remaining Cash Balance	Not explicitly reported for 2025	Last reported cash and equivalents balance was $4.9 million as of March 31, 2024.
Minimal Residual Revenue (Inventory/Equipment)	Not explicitly reported for 2025	This would represent final wind-down sales, if any, post-acquisition.

The old model, reliant on consumables, is confirmed to be obsolete for the entity Motus GI Holdings, Inc. as an independent operator:

• The old revenue from disposable sleeves (Q1 2024 was only $64,000) is now gone.

To be fair, that Q1 2024 sleeve revenue of $64,000 was the last gasp of the razor-and-blade component of the business model before the Chapter 7 filing and asset sale.

The structure of the final capital event is key to understanding the current financial state, which is now tied to the proceeds of that transaction:

• The asset sale to CONMED Corporation for approximately $14 million in Q1 2024 provided the main source of current capital.
• The cash and cash equivalents balance as of March 31, 2024, was $4.9 million.
• Net cash used in operating activities for the three months ended March 31, 2024, was $2.0 million.

Finance: draft 13-week cash view by Friday.